Fig 1: B7-H3 suppressed the cytotoxic effect of Vδ2 T cells against colon cancer cells by downregulating the perforin and granzyme pathway.(A) The protein levels of perforin and granzyme B in Vδ2 T cells treated with B7-H3 siRNA or NC siRNA were detected by ELISA. (B) The cytotoxicity of Vδ2 T cells pretreated with B7-H3 siRNA and CMA or BCL-2 against HCT116 or RKO cells was analyzed by CCK-8 assay. (C, D) The number (NO.) and size (area) of clusters of Vδ2 T cells pretreated with B7-H3 siRNA and CMA or BCL-2 around HCT116 (C) and RKO (D) cells. (E) The protein levels of perforin and granzyme B in Vδ2 T cells treated with 4H7 or IgG were detected by ELISA. (F) The cytotoxicity of Vδ2 T cells pretreated with 4H7 and recombinant granzyme B (GZMB) against HCT116 or RKO cells was analyzed by CCK-8 assay. (G, H) The number (NO.) and size (area) of clusters of Vδ2 T cells pretreated with 4H7 and recombinant granzyme B (GZMB) around HCT116 (G) and RKO (H) cells. Values are expressed as means ± SD. *p < .05, **p < .01, ***p < .001.
Fig 2: The BH3-like region of ApoL1 does not bind to Bcl-2 family members.a Alignment of the 25-mer peptides encompassing the BH3-like region of ApoL1 and ApoL2 and the BH3-only motif of Bid and Bim. The BH3-only motif Φ1sxxΦ2xxΦ3sDzΦ4B contains four hydrophobic residues Φ1–Φ4, small residues “s” (e.g. Gly, Asp, Ser), an acidic residue “D,” and an H-bond acceptor “B.” Highlighted are the potentially problematic Ile residue of ApoL1 and ApoL2 (purple) and the hallmark residues Leu (Φ2) and Asp (D) (both in red), which engage in binding to Bcl-2 proteins. The asterisk indicates the position of E150 of the ApoL1-E150/I228/K255 haplotype. b The BH3-like helix of ApoL1 from the NMR structure (cyan) and the Fab7D6:ApoL1-BH3 peptide structure (green) superimpose well with the Bid BH3-only helix (gold; from PDB 4QVE). Key residues including leucine (Φ2, underlined) and aspartic acid (D, underlined) are shown as sticks. c Representative results from SPR experiments showing single-cycle kinetics of the binding interactions between immobilized Bcl-xL and its ligands Bid (KD 7.1 ± 0.9 nM) and Bim (KD 3.3 ± 1.2 nM) and the lack of binding to the ApoL1-BH3 peptide, the ApoL1-NTD and ApoL1 (up to 3 µM concentration). The change of the ApoL1 residue I155 to the canonical small residue alanine (ApoL1-BH3 (I155A)) did not confer any detectable interaction (up to 3µM concentration). All experiments were done in triplicate and repeated at least three times.
Supplier Page from R&D Systems, a Bio-Techne Brand for Recombinant Human Bcl-2 (minus C-Terminus) Protein, CF